HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Oncology
Sys. Review
Antibody-drug conjugates are expanding from late-line to first-line combination regimens in lung cancer
New Drug Class Shifts Lung Cancer Treatment Toward First-Line Use
This narrative review examines the expanding role of antibody-drug conjugates (ADCs) in non-small cell lung cancer (NSCLC) and small cell lu…
A new class of cancer drugs is moving from last-resort treatment to first-line therapy for lung cancer, but early data need confirmation.
Frontiers
Oct 9, 2026
Allergy & Immunology
Meta-analysis
Later-line antibody-drug conjugates show 25.7% objective response rate in advanced small-cell lung cancer
Antibody-drug conjugates show activity in advanced small-cell lung cancer
This systematic review and meta-analysis evaluates later-line monotherapy with antibody-drug conjugates (ADCs) for advanced small-cell lung …
Antibody-drug conjugates show promise for treating advanced small-cell lung cancer, though they are associated with frequent clinical toxici…
Frontiers
Oct 7, 2026
Allergy & Immunology
Sys. Review
Narrative review discusses antibody targeting of the TNF–TNFR2 axis in cancer with noted limitations
Antibodies targeting TNFR2 show promise for cancer treatment
This narrative review examines antibody targeting of the TNF–TNFR2 axis, including monoclonal antibodies, antibody–drug conjugates, and bisp…
A narrative review suggests antibodies targeting the TNF–TNFR2 axis may offer new cancer treatment options, though more research is needed.
Frontiers
May 18, 2026